Research programme: CAR-T cell based therapeutics - Autolus

Drug Profile

Research programme: CAR-T cell based therapeutics - Autolus

Alternative Names: Engineered T-cell immunotherapeutics- Autolus

Latest Information Update: 03 Apr 2017

Price : $50

At a glance

  • Originator University College London
  • Developer Autolus
  • Class Antineoplastics; CAR-T cell therapies
  • Mechanism of Action Cytotoxic T lymphocyte stimulants; Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Multiple myeloma; T cell lymphoma

Most Recent Events

  • 22 Mar 2017 Pharmacodynamics data from preclinical trial in Multiple myeloma presented at the American Society of Hematology 58th Annual Meeting (ASH-Hem-2016)
  • 21 Mar 2017 CAR-T cell based therapeutics - Autolus is available for licensing as of 21 Mar 2017. http://www.autolus.com/about-us/overview
  • 05 Dec 2016 Pharmacodynamics data from preclinical trial in T-cell lymphoma presented at the American Society of Hematology 58th Annual Meeting (ASH-Hem-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top